Active Ingredient(s): Pertuzumab
FDA Approved: * June 8, 2012
Pharm Company: * GENENTECH
Category: Cancer

Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.[2] Side effects in more than half the people taking it include diarrhea, hair loss, and loss of neutrophils; more than 10% experience loss of red blood cells, hypersensitivity or allergic reaction, infusio... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Perjeta 30 mg/ml Intravenous Injection, Solution, Concentrate
NDC: 50242-145
Genentech, Inc.

Popular Topics

Side Effects of Perjeta?

Has anyone experienced cold like symptoms for an extended length of time after their last Perjeta infusion? I have had a...